In this test, TRPA1 antagonist HC-030031 demonstrated no statistically significant antiallodynic properties in both phases of oxaliplatin-induced peripheral neuropathy, administered at doses 1.5 and 10 mg/kg. This evidence concerns the gene TRPA1 and peripheral neuropathy.